While UroGen Pharma Ltd has overperformed by 0.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, URGN fell by -46.55%, with highs and lows ranging from $20.70 to $3.42, whereas the simple moving average fell by -35.78% in the last 200 days.
On May 22, 2025, H.C. Wainwright Downgraded UroGen Pharma Ltd (NASDAQ: URGN) to Neutral. A report published by Scotiabank on April 16, 2025, Initiated its previous ‘Sector Outperform’ rating for URGN. Ladenburg Thalmann also rated URGN shares as ‘Buy’, setting a target price of $31 on the company’s shares in an initiating report dated February 19, 2025. Guggenheim Initiated an Buy rating on August 22, 2024, and assigned a price target of $40. Jefferies February 08, 2023d its ‘Buy’ rating to ‘Hold’ for URGN, as published in its report on February 08, 2023. Berenberg’s report from April 27, 2022 suggests a price prediction of $20 for URGN shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of UroGen Pharma Ltd (URGN)
Further, the quarter-over-quarter increase in sales is 7.84%, showing a positive trend in the upcoming months.
UroGen Pharma Ltd’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. Taking into account the quick ratio of the company, currently set at 5.47, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and URGN has an average volume of 1.66M. On a monthly basis, the volatility of the stock is set at 17.97%, whereas on a weekly basis, it is put at 18.42%, with a gain of 41.00% over the past seven days. Furthermore, long-term investors anticipate a median target price of $24.62, showing growth from the present price of $7.05, which can serve as yet another indication of whether URGN is worth investing in or should be passed over.
How Do You Analyze UroGen Pharma Ltd Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.66%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
